Other

University of California

Leland Stanford Junior University

Friedrich-alexander-universitat Erlangen-nürnberg

Harald Huebner

Peter Gmeiner

Brian K Kobilka

Roger K Sunahara

Miriam Ruberg

Jeremy Shonberg

Mary Joyce Clark

Anne Stößel

Luis Maul

Markus Stanek

Dorothée Möller

Aspects of the present disclosure include conformationally restricted analogs of catecholamine type compounds (e.g., isoprenaline, adrenaline, noradrenaline) which activate &#x3b2;2AR with high selectivity over &#x3b2;1AR. The subject beta-2 selective adrenergic receptor agonist compounds may serve as bronchiodilators and find use in the treatment of a variety of bronchoconstrictive diseases and conditions. Also provided are compositions and methods for treating preterm labor. A method of treating acute asthma including administration of a subject compound to a subject in need thereof is provided. The subject method can provide for reduced undesirable side effects associated with non-selective &#x3b2;-adrenergic receptor agonism, such as inotropic and chronotropic effects that leads to elevated blood pressure. The compounds can also be used to prevent or treat heart failure. Kits and compositions for practicing the subject methods are also provided.

Beta-2 selective adrenergic receptor agonists

The present application relates generally to amino tetraline derivative compounds and methods of use, specifically, embodiments including compounds of formula (I) described herein, pharmaceutically acceptable salts and solvates. More specifically, this application relates to amino tetraline derivative compounds and uses of such compounds producing medicaments for the treatment of various disease and conditions including movement disorders and disorders of the central nervous system.

Aminotetraline derivatives

Growing community of inventors

Heroldsbach, Germany

Harald Huebner